Context Therapeutics Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Context Therapeutics Inc. (Nasdaq: CNTX) develops T cell engaging bispecific antibody therapies for the treatment of solid tumors, primarily targeting difficult-to-treat cancers including those expressing Claudin 6, mesothelin and Nectin-4. The company's lead product candidates include CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody in Phase 1 dose-escalation trials demonstrating preliminary antitumor activity with no cytokine release syndrome above Grade 1 or dose-limiting toxicities as of late 2025; CT-95, an avidity-enhanced mesothelin (MSLN) x CD3 bispecific antibody in Phase 1 with six patients enrolled across Cohorts 1-3 and no maximum tolerated dose reached; and CT-202, a dual pH-dependent Nectin-4 x CD3 bispecific antibody advancing toward a first-in-human trial filing in Q2 2026. Context Therapeutics maintains a collaboration and license agreement with Integral Molecular Inc. for CLDN6 bispecific antibody development. Founded in 2015 and headquartered at 2001 Market Street in Philadelphia, Pennsylvania, the company operates in the United States with approximately 12 employees focused on oncology innovation. Recent developments include Q3 2025 financial results showing $76.9 million in cash to fund operations into 2027 alongside a reduced net loss of $9.7 million; appointment of Dr. Karen Chagin as Chief Medical Officer in June 2025; poster presentations on CT-95 and CT-202 at the SITC 40th Annual Meeting in November 2025; and ongoing Phase 1 enrollment for CTIM-76 and CT-95 with initial data anticipated in 2026.
Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Contrasting Galectin Therapeutics (NASDAQ:GALT) & Context Therapeutics (NASDAQ:CNTX)
Context Therapeutics Reports Full Year 2025 Operating and Financial Results
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
Context Therapeutics CEO Teases Q2 Claudin 6 Data, Nectin-4 Clinic Entry at TD Cowen Conference
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Average Recommendation of “Moderate Buy” from Brokerages
Context Therapeutics to Participate in Upcoming Investor Conferences
Financial Comparison: Context Therapeutics (NASDAQ:CNTX) vs. Carisma Therapeutics (NASDAQ:CARM)
Sandoz Group (OTCMKTS:SDZNY) versus Context Therapeutics (NASDAQ:CNTX) Head-To-Head Contrast
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Context Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Context Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Context Therapeutics (NASDAQ:CNTX) Shares Up 8.7% – What’s Next?